In the I-SPY 2 adaptive phase II trial of neoadjuvant HER2-positive breast cancer, neratinib was administrated based on the chemotherapy of paclitaxel, and achieved an ideal pCR rate threshold in the HR-negative group (56%, 95% Bayesian probability interval [PI]: 37 to 73%), significantly higher than the trastuzumab group (33%, 95% PI: 11 to 54%) (27). This evidence concerns the gene ERBB2 and breast cancer.